Global Non-Cancerous Blood Disease Market Highlights Over 2021 - 2031
The global non-cancerous blood disease market is estimated to garner a revenue of USD 105972.8 Million by the end of 2031, by growing at a CAGR of 6.40% over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a revenue of USD 57224.1 Million in the year 2021. The growth of the market can be attributed to the growing prevalence of several non-cancerous blood disorders, such as hemoglobinopathies, platelet & coagulation related disorders, anemia, sickle cell disease, hemophilia, and thalassemia among others. For instance, according to the statistics by the World Health Organization (WHO), in the year 2019, the global prevalence of anemia recorded to be 29.9% in women of reproductive age, 29.6% in non-pregnant women of reproductive age, and 36.5% in pregnant women. Additionally, in children between the ages 6 and 59 months, the prevalence of the disease in the same year was 39.8%.
Get more information on this report: Request Sample PDF
The market growth can also be attributed to the growing burden of hemoglobinopathies, backed by the increasing migration of population to higher-income countries from low- as well as middle-income nations. The human migration is expected to continue at an increasing rate amid globalization. Consequently, the number of hemoglobinopathies immigrants is also expected to grow, supported by population growth and transition to public health. Besides this, the increasing need for early diagnosis of these diseases, followed by the rapid advancements in the development of orphan drugs, along with the emerging research activities in the development of advanced drugs and therapies are also expected to boost the market growth in the coming years.
Global Non-Cancerous Blood Disease Market Regional Synopsis
Regionally, the global non-cancerous blood disease market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Europe region is anticipated to garner the largest revenue of USD 39845.4 Million by the end of 2031, up from a revenue of USD 21344.6 Million in the year 2021. The growth of the market in the region can primarily be attributed to the growing awareness for non-cancerous blood diseases, along with the rising concern for the increasing economic burden of non-malignant blood disorders. Besides this, the increasing prevalence of these diseases is also expected to contribute to the market growth in the coming years. According to the World Bank, the prevalence of anemia among children (% of children ages 6-59 months) in the European Union increased from 13.86% in the year 2007 to 16.084% in the year 2019.
The market in the region is further segmented by country into Germany, United Kingdom, Italy, France, Russia, and the Rest of Europe. The market in Germany is anticipated to garner the second-largest revenue of USD 7736.2 Million by the end of 2031, up from a revenue of USD 3863.4 Million in the year 2021.
The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Growth Drivers and Challenges Impacting the Growth of the Global Non-Cancerous Blood Disease Market
Growth Drivers
- Increasing Prevalence of Various Non-Cancerous Blood Disorders
- Growing Number of Hemoglobinopathies Immigrants
- Escalating Need for Early Diagnosis of Diseases
Challenges
- High Cost of Treatment of These Diseases
- Complexities in Monitoring Several Non-Malignant Blood Disorders
Global Non-Cancerous Blood Disease Market Segmentation Synopsis
The global non-cancerous blood disease market is segmented by disorder type into anemia, bleeding disorders, platelet disorders, white blood cell disorders, plasma cell disorders, rare hematological disorders, and spleen disorders. Out of these, the bleeding disorders segment is projected to display the largest revenue of USD 29949.69 Million by the end of 2031, up from a revenue of USD 16570.67 Million in the year 2021. By treatment type, the market is segmented into antibiotics, blood transfusion, infusion therapy, dietary supplements or chelators, and others. Out of these, the blood transfusion segment is anticipated to garner the second-largest revenue of USD 22268.46 Million by the end of 2031, up from a revenue of USD 12120.08 Million in the year 2021. By gender, the market is segmented into male, and female, out of which, the female segment is projected to garner the highest market share by the end of 2031. By end-user, the market is segmented into hospitals, clinics, and others. Out of these, the hospitals segment is anticipated to garner the largest revenue of USD 57466.34 Million by the end of 2031, up from a revenue of USD 31059.08 Million in the year 2021.
Key Companies Dominating the Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global non-cancerous blood disease market that are included in our report are SANOFI, Novo Nordisk A/S, Novartis AG, Pfizer Inc., Amgen Inc., Alexion Pharmaceuticals, Inc., Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, CSL Behring, and others.
Key Reasons to Buy Our Report
- The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
- It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
- The report includes detailed company profiles of the major players dominating the market.
- We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
- We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
